Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: A cost-effective treatment?

Ophthalmic Surgery Lasers and Imaging

Volumn 36, Issue 4, 2005, Pages 270-271

  Reichel, Elias ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

CENTRAL RETINA VEIN OCCLUSION; COST EFFECTIVENESS ANALYSIS; DRUG PENETRATION; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; HUMAN; LASER SURGERY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

EID: 23044473246     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/1542-8877-20050701-03     Document Type: Editorial

References (6)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
2. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
6. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544.